羚锐制药
(600285)
| 流通市值：122.91亿 | | | 总市值：123.18亿 |
| 流通股本：5.66亿 | | | 总股本：5.67亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,126,074,496.05 | 3,853,391,129.7 | 3,041,361,639.17 | 2,099,205,515.81 |
| 营业收入 | 1,126,074,496.05 | 3,853,391,129.7 | 3,041,361,639.17 | 2,099,205,515.81 |
| 二、营业总成本 | 848,497,974.23 | 3,029,670,519.08 | 2,332,076,667.21 | 1,580,082,239.98 |
| 营业成本 | 245,621,730.85 | 769,552,146.93 | 577,299,015.5 | 391,972,006.89 |
| 税金及附加 | 13,909,677.29 | 51,726,101.5 | 40,908,722.15 | 28,113,444.44 |
| 销售费用 | 527,336,627.13 | 1,828,759,703.53 | 1,437,387,330.38 | 994,497,354.35 |
| 管理费用 | 36,249,379.91 | 215,598,513.87 | 176,993,366.27 | 106,577,838.9 |
| 研发费用 | 31,483,551.8 | 169,124,390.58 | 104,600,773.85 | 63,060,862.63 |
| 财务费用 | -6,102,992.75 | -5,090,337.33 | -5,112,540.94 | -4,139,267.23 |
| 其中:利息费用 | 763,973.76 | 3,900,518.95 | 3,260,401.6 | 1,596,630.86 |
| 其中:利息收入 | 6,978,107.61 | 9,728,108.53 | 8,592,375.19 | 6,040,838.42 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 834,073.38 | -7,324,507.63 | 800,729.64 | -1,998,717.96 |
| 加:投资收益 | 11,026,112.95 | 49,996,026.1 | 36,727,423.67 | 24,131,253.21 |
| 资产处置收益 | -3,753.24 | 6,993,442.94 | 4,739,381.35 | 4,703,827.72 |
| 资产减值损失(新) | -48,281.4 | -608,216.19 | -58,216.77 | -35,682.24 |
| 信用减值损失(新) | -8,547,079.86 | -5,331,455.25 | -9,625,302.34 | -6,382,347.75 |
| 其他收益 | 4,416,009.2 | 19,828,005.08 | 16,495,599.62 | 11,929,463.94 |
| 四、营业利润 | 285,253,602.85 | 887,273,905.67 | 758,364,587.13 | 551,471,072.75 |
| 加:营业外收入 | 316,089 | 1,700,000.77 | 1,415,536.05 | 1,285,243.01 |
| 减:营业外支出 | 57,774.96 | 9,508,275.16 | 2,221,330.37 | 1,208,773.01 |
| 五、利润总额 | 285,511,916.89 | 879,465,631.28 | 757,558,792.81 | 551,547,542.75 |
| 减:所得税费用 | 38,070,005.91 | 117,017,775.43 | 104,022,269.61 | 75,679,042.87 |
| 六、净利润 | 247,441,910.98 | 762,447,855.85 | 653,536,523.2 | 475,868,499.88 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 247,441,910.98 | 762,447,855.85 | 653,536,523.2 | 475,868,499.88 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 246,333,622.73 | 759,503,032.53 | 650,932,609.77 | 474,385,806.53 |
| 少数股东损益 | 1,108,288.25 | 2,944,823.32 | 2,603,913.43 | 1,482,693.35 |
| 扣除非经常损益后的净利润 | 227,551,542.24 | 711,549,474.02 | 605,225,066.74 | 442,499,140.75 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.44 | 1.34 | 1.15 | 0.84 |
| (二)稀释每股收益 | 0.43 | 1.34 | 1.15 | 0.83 |
| 八、其他综合收益 | -71,032.45 | 42,390,202.71 | 4,885,283.79 | 6,235,719.57 |
| 归属于母公司股东的其他综合收益 | -86,981.68 | 42,425,136.57 | 4,864,027.4 | 6,223,701.99 |
| 九、综合收益总额 | 247,370,878.53 | 804,838,058.56 | 658,421,806.99 | 482,104,219.45 |
| 归属于母公司股东的综合收益总额 | 246,246,641.05 | 801,928,169.1 | 655,796,637.17 | 480,609,508.52 |
| 归属于少数股东的综合收益总额 | 1,124,237.48 | 2,909,889.46 | 2,625,169.82 | 1,494,710.93 |
| 公告日期 | 2026-04-28 | 2026-04-28 | 2025-10-30 | 2025-08-20 |
| 审计意见(境内) | | 标准无保留意见 | | |